Dronedarone

Chemical formula: C₃₁H₄₄N₂O₅S  Molecular mass: 556.756 g/mol  PubChem compound: 208898

Therapeutic indications

Dronedarone is indicated for:

Maintenance of sinus rhythm after successful cardioversion of paroxysmal or persistent atrial fibrillation (AF)

Population group: only adults (18 years old or older)

Dronedarone is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, dronedarone should only be prescribed after alternative treatment options have been considered.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Dronedarone is contraindicated in the following cases:

Second degree atrio-ventricular block

Second degree atrioventricular block

Third degree atrio-ventricular block

Complete atrioventricular block

Complete bundle branch block

at least one of
Complete left bundle branch block
Complete right bundle branch block

Sinus node dysfunction

Coronary sinus rhythm disorder

Atrial conduction defects

Atrial septal defect, atrioventricular conduction defect syndrome

Sick sinus syndrome

Sick sinus syndrome

Bradycardia

Bradycardia

Permanent AF with an AF duration ≥6 months (or duration unknown)

Permanent atrial fibrillation

Unstable hemodynamic conditions

Haemodynamic instability

Left ventricular systolic dysfunction

Left ventricular systolic dysfunction

History of, or current heart failure

Cardiac failure

Liver and lung toxicity related to amiodarone

at least one of
Cirrhosis of liver caused by amiodarone
Drug induced interstitial lung disease and additionally Amiodarone

Potent cytochrome P 450 (CYP) 3A4 inhibitors

Strong CYP3A4 inhibitors

Medicinal products inducing torsades de pointes

Drugs inducing Torsade de Pointes

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment (CrCl <30 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Dabigatran

Dabigatran

Erythromycin

Erythromycin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: MULTAQ Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈